TORONTO, June 23, 2011 /CNW/ - Amorfix Life Sciences Ltd., a product
development company focused on diagnostics and therapeutics for
misfolded protein diseases, announced today that the company is
currently being featured on the television program Today in America with Terry Bradshaw. The program describes the Company's efforts to develop a new test for
the diagnosis of Alzheimer's disease. The program will be aired over
the next few weeks in multiple regions throughout the United States and
has been placed on the Corporate website available for public viewing (www.amorfix.com).
"The program highlights the pioneering work that Amorfix has performed
in the area of new diagnostics for the accurate diagnosis of
Alzheimer's disease", said Dr. Robert Gundel, Amorfix Chief Executive
Officer. Our technology enables the identification and subsequent
measurement of misfolded proteins that are present in an excess of
normally folded proteins. In the case of Alzheimer's disease, we have
demonstrated the ability to measure aggregated Abeta amyloid in the
cerebrospinal fluid of Alzheimer's patients. Abeta amyloid is a
misfolded protein which is known to be the building block of plaque
formation in the brains of Alzheimer's disease patients and is a known
biomarker for the disease. This work represents an important step in
the direction of having a new diagnostic tool available for the early
and accurate diagnosis of Alzheimer's disease and the potential to
identify patients with mild cognitive impairment who may progress to
Alzheimer's disease. We believe that this is the most important area
for a new diagnostic since there is currently no way to identify
patients showing initial signs of dementia who will progress into
"Today there are more than 5 million people with Alzheimer's disease in
North America and the numbers are expected to grow at an alarming rate
over the next 20 to 30 years making this one of the most significant
healthcare issues" said Dr. Neil Cashman, Amorfix Chief Scientific
Officer. The development of a new diagnostic that can detect the onset
of Alzheimer's disease early will be an important part of our success
in getting new treatments on the market as soon as possible."
Alzheimer's disease is a chronic neurodegenerative disease characterized
in part by memory loss, confusion, disorientation, and mood changes.
Currently, the only definitive diagnostic for Alzheimer's disease is
post-mortem examination of brain tissue to detect neurofibrillary
tangles and deposits of aggregated misfolded Abeta amyloid in plaques
in and around neural tissue.
Amorfix Life Sciences Ltd. (TSX:AMF) is a product development company
developing therapeutic products and diagnostic devices targeting
misfolded protein diseases including Alzheimer's Disease (AD), cancers,
and ALS. Amorfix utilizes its computational discovery platform,
ProMIS™, to predict novel Disease Specific Epitopes ("DSEs") on the
molecular surface of misfolded proteins. Amorfix's lead programs
include therapeutics and companion diagnostics for cancers, antibodies
and vaccines to DSEs in ALS and AD diagnostic tests. In addition,
Amorfix's proprietary Epitope Protection™ technology enables it to
specifically identify very low levels of misfolded proteins in a
biological sample. The Company's diagnostic programs include an
ultrasensitive method for the detection of aggregated beta-Amyloid in
brain tissue, CSF and blood from animal models of AD, months prior to
observable amyloid formation, and development of a human screening test
for AD. For more information about Amorfix, visit www.amorfix.com.
This press release may contain certain forward-looking information. Such
information involves known and unknown risks, uncertainties and other
factors that may cause actual results, performance or achievements to
be materially different from those implied by statements herein, and
therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on the
Company's current beliefs as well as assumptions made by and
information currently available to it as well as other factors.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. Due to risks and uncertainties, including the risks and
uncertainties identified by the Company in its public securities
filings, actual events may differ materially from current expectations.
The Company disclaims any intention or obligation to update or revise
any forward-looking statements, whether as a result of new information,
future events or otherwise.
SOURCE Amorfix Life Sciences Ltd.
For further information:
| Dr. Robert Gundel |
President and Chief Executive Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6957
Fax: (416) 847-6899
| || || Janet Clennett |
Acting Chief Financial Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6926
Fax: (416) 847-6899